Q&A: As RSV vaccine approvals loom, regulators need to devise vaccination strategies
Pharmaceutical Technology
MAY 1, 2023
After a US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) Advisory Committee (AdCom) meeting in March 2023 voted unanimously in support of GSK’s respiratory syncytial virus vaccine, the odds for an approval have increased. This interview has been edited for length and clarity.
Let's personalize your content